TITLE

Help for Alzheimer's

PUB. DATE
May 1991
SOURCE
New Scientist;5/4/91, Vol. 130 Issue 1767, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Announces the possible benefit to Alzheimers patients of a drug called tacrine. Tests of the drug by researchers at England's Institute of Psychiatry; Inhibition of the activity of the enzyme cholinesterase; Withdrawal of some patients from the trial because of problems caused by the drug.
ACCESSION #
9105273186

 

Related Articles

  • Tacrine offers long-term safety and efficacy for Alzheimer's patients.  // Brown University Long-Term Care Quality Letter;1/30/95, Vol. 7 Issue 2, p6 

    Reports on the effectiveness of tacrine to treat persons afflicted with Alzheimer's disease. Findings of study conducted by the Institute of Psychiatry in London, England; Liver function of patients administered tacrine; Progression in disease among patients.

  • LATEST CLINICAL TRIAL DATA ON DISEASE-MODIFYING THERAPIES FROM THE 2008 INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE. R. Z. // Primary Psychiatry;Sep2008, Vol. 15 Issue 9, p24 

    The article reports on clinical trial results which examined potential treatment for Alzheimer's disease presented at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease in Chicago, Illinois. There were slightly higher incidences of anemia, infections and...

  • Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease. Ott, Brian R.; Blake, Lesley M.; Kagan, Ethel; Resnick, Malca // Journal of Neurology;Mar2007, Vol. 254 Issue 3, p351 

    Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be safe and to have beneficial effects on cognition, function, behavior, and global patient status in patients with Alzheimer’s disease (AD) in studies lasting 3–6 months. It is approved in the U.S....

  • An Overview of Phytotherapeutic Approach in Prevention and Treatment of Alzheimer's Syndrome & Dementia. Singh, Narendra; Pandey, B. R.; Verma, Pankaj // International Journal of Pharmaceutical Sciences & Drug Research;Jul-Sep2011, Vol. 3 Issue 3, p162 

    Alzheimer disease (AD) is the most common form of the dementia which occurs among older people above the age of 60 years. The Alzheimer's disease once considered a rare disorder and it is now seen as a major public health problem that is seriously affecting millions of older people and their...

  • Preparation and in vitro and in vivo evaluation of HupA PLGA Microsphere. Liang Ye; Fenghua Fu; Wanhui Liu; Kaoxiang Sun; Youxin Li; Xin Yu; Jie He; Pengfei Yu; Jingwei Tian // Pakistan Journal of Pharmaceutical Sciences;Mar2013, Vol. 26 Issue 2, p315 

    Acetylcholinesterase inhibitors (AChEIs), including Huperzine A (HupA), have been the mainstay of treatment for Alzheimer's disease (AD). However, AChEIs can cause gastrointestinal side effects, which has been related to the high Cmax and short tmax after oral administration. Clinical trials...

  • Merck announces encouraging data from Phase I Alzheimer's disease trial.  // PharmaWatch: CNS;Jun2012, Vol. 11 Issue 6, p18 

    The article reports on the data from Merck & Co. Inc.'s Phase I Alzheimer's disease trial which examines the safety and tolerability of oral betaamyloid precursor protein site cleaving enzyme, or BACE, inhibitor, MK-8931. It notes that single doses of the said drug were linked to the reductions...

  • Multiple drugs.  // Reactions Weekly;5/1/2013, Issue 1450, p24 

    An abstract of the study "Do medicines with aim to anti-Alzheimer favor the arisen of epileptic crisis? Discussion about 3 clinical cases," by M. Roy and colleagues is presented.

  • Drugs for Alzheimer's Offer a Measure of Relief.  // Tufts University Health & Nutrition Letter;May2001, Vol. 19 Issue 3, p7 

    Presents information on the drug Reminyl, which helps mitigate the symptoms of Alzheimer's disease. How the drug works; Other Alzheimer drugs available in the market; Side effects of Alzheimer's drugs.

  • Donepezil.  // Reactions Weekly;1/30/2010, Issue 1286, p16 

    The article describes the case of an 83-year-old woman with Alzheimer's disease who developed torsade de pointes and QT prolongation during treatment with donepezil.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics